il34-modulation-therapy

Migration, Crosslink

📖

il34-modulation-therapy

active

wiki page Created: 2026-04-02T07:19:02 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-il34-modulation-therap

📖 Wiki Page

therapeutic1225 wordssynced 2026-04-02

IL-34 Modulation Therapy for Neurodegeneration

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">il34-modulation-therapy</th>
</tr>
<tr>
<td class="label">Pathway</td>
<td>Primary Effect</td>
</tr>
<tr>
<td class="label">PI3K/Akt</td>
<td>Cell survival</td>
</tr>
<tr>
<td class="label">MAPK/ERK</td>
<td>Proliferation</td>
</tr>
<tr>
<td class="label">JAK/STAT</td>
<td>Gene transcription</td>
</tr>
<tr>
<td class="label">PLCγ</td>
<td>Calcium signaling</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Type</td>
</tr>
<tr>
<td class="label">Recombinant IL-34</td>
<td>Protein</td>
</tr>
<tr>
<td class="label">CSF1R agonists</td>
<td>Small molecules</td>
</tr>
<tr>
<td class="label">IL-34/CSF1R axis modulators</td>
<td>Biologicals</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Target</td>
</tr>
<tr>
<td class="label">PLX3397 (Pexidartinib)</td>
<td>CSF1R antagonist</td>
</tr>
<tr>
<td class="label">PLX5622</td>
<td>CSF1R antagonist</td>
</tr>
<tr>
<td class="label">BLZ945</td>
<td>CSF1R antagonist</td>
</tr>
<tr>
<td class="label">Strategy</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">IL-34 protein</td>
<td>Direct CSF1R activation</td>
</tr>
<tr>
<td class="label">CSF1R agonists</td>
<td>Enhanced receptor signaling</td>
</tr>
<tr>
<td class="label">CSF1R antagonists</td>
<td>Reduce microglial proliferation</td>
</tr>
<tr

...

IL-34 Modulation Therapy for Neurodegeneration

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">il34-modulation-therapy</th>
</tr>
<tr>
<td class="label">Pathway</td>
<td>Primary Effect</td>
</tr>
<tr>
<td class="label">PI3K/Akt</td>
<td>Cell survival</td>
</tr>
<tr>
<td class="label">MAPK/ERK</td>
<td>Proliferation</td>
</tr>
<tr>
<td class="label">JAK/STAT</td>
<td>Gene transcription</td>
</tr>
<tr>
<td class="label">PLCγ</td>
<td>Calcium signaling</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Type</td>
</tr>
<tr>
<td class="label">Recombinant IL-34</td>
<td>Protein</td>
</tr>
<tr>
<td class="label">CSF1R agonists</td>
<td>Small molecules</td>
</tr>
<tr>
<td class="label">IL-34/CSF1R axis modulators</td>
<td>Biologicals</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Target</td>
</tr>
<tr>
<td class="label">PLX3397 (Pexidartinib)</td>
<td>CSF1R antagonist</td>
</tr>
<tr>
<td class="label">PLX5622</td>
<td>CSF1R antagonist</td>
</tr>
<tr>
<td class="label">BLZ945</td>
<td>CSF1R antagonist</td>
</tr>
<tr>
<td class="label">Strategy</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">IL-34 protein</td>
<td>Direct CSF1R activation</td>
</tr>
<tr>
<td class="label">CSF1R agonists</td>
<td>Enhanced receptor signaling</td>
</tr>
<tr>
<td class="label">CSF1R antagonists</td>
<td>Reduce microglial proliferation</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Company</td>
</tr>
<tr>
<td class="label">IL-34 recombinant</td>
<td>Various</td>
</tr>
<tr>
<td class="label">Anti-IL-34 antibodies</td>
<td>Research</td>
</tr>
<tr>
<td class="label">CSF1R modulators</td>
<td>Plexxikon/Novartis</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Target</td>
</tr>
<tr>
<td class="label">IL-34 agonists</td>
<td>IL-34</td>
</tr>
<tr>
<td class="label">Anti-IL-34 antibodies</td>
<td>IL-34</td>
</tr>
<tr>
<td class="label">CSF1R inhibitors</td>
<td>CSF1R</td>
</tr>
<tr>
<td class="label">TREM2 modulators</td>
<td>TREM2</td>
</tr>
</table>

Introduction

IL-34 Modulation Therapy encompasses therapeutic strategies targeting interleukin-34 (IL-34), a cytokine that serves as the primary ligand for the colony-stimulating factor 1 receptor (CSF1R) in the central nervous system. IL-34 plays a critical role in microglial survival, proliferation, and function, making it an attractive target for neurodegenerative disease therapy. [@lin2013]

The IL-34/CSF1R axis has emerged as a pivotal pathway in Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS). Therapeutic approaches include both agonism (to enhance neuroprotective microglial function) and antagonism (to reduce pathogenic microglial activation), depending on disease stage and context. [@chihara2016]

Mechanism of Action

IL-34/CSF1R Signaling Pathway

IL-34 signals through CSF1R to regulate microglial biology:

Receptor activation: IL-34 binds CSF1R extracellular domain, inducing dimerization

Intracellular signaling: Autophosphorylation activates downstream cascades

Cellular responses: Survival, proliferation, differentiation, and phenotype modulation

Signaling Pathways Activated

Therapeutic Rationale

The therapeutic strategy depends on disease context:

IL-34 Agonism: Early-stage disease where enhanced microglial function may be protective
IL-34 Antagonism: Late-stage disease where excessive microglial activation drives pathology

Therapeutic Strategies

IL-34 Agonists

Rationale for agonism:

IL-34 expression is reduced in AD and PD brain [@easter2018]
Enhancing IL-34 signaling may restore microglial homeostatic function
Supports oligodendrocyte differentiation and remyelination [@wang2021]

IL-34 Neutralizing Antibodies

A novel therapeutic approach using antibodies to neutralize excessive IL-34 signaling:

Target: Block IL-34 binding to CSF1R
Indications: Late-stage AD where excessive IL-34 may drive harmful microgliosis
Development: Preclinical/early research [@yang2022]

Rationale for antagonism:

Some studies show elevated IL-34 in specific disease contexts
Blocking excessive signaling may reduce chronic inflammation
May be beneficial when microglial proliferation contributes to pathology

CSF1R Modulation

Since IL-34 signals exclusively through CSF1R, CSF1R-targeted approaches effectively modulate the IL-34 pathway:

See [CSF1R Modulation Therapy](/therapeutics/csf1r-modulation-therapy) for detailed information.

Disease-Specific Applications

Alzheimer's Disease

IL-34 dysregulation in AD presents both challenges and opportunities:

Reduced neuronal IL-34: 40-70% decrease in AD brain tissue
Correlation with pathology: Changes correlate with amyloid burden and cognitive decline
CSF biomarker potential: IL-34 levels in cerebrospinal fluid correlate with disease stage

Therapeutic approaches:

Early AD: IL-34/CSF1R agonism to enhance microglial Aβ clearance

Late AD: Modulation or blockade of excessive IL-34 signaling

Combination: With anti-amyloid immunotherapies

Key evidence:

IL-34 administration reduces amyloid pathology in mouse models [@boi2018]
IL-34 affects tau pathology progression [@liu2021]
Single-cell analysis reveals altered IL-34-expressing cells in AD brain [@zhang2022]

Parkinson's Disease

In Parkinson's disease, IL-34 modulation shows promise:

Reduced IL-34: Decreased expression in substantia nigra
α-Synuclein interactions: IL-34 affects microglial clearance of α-synuclein aggregates

Therapeutic approaches: Key evidence:

IL-34 administration protects against dopaminergic neuron loss in PD models [@mugantseva2019]
IL-34 enhances α-synuclein clearance by microglia [@wu2023]
Recent study links IL-34 to α-synuclein pathology progression [@xie2024]

Amyotrophic Lateral Sclerosis (ALS)

IL-34 alterations in ALS:

Changed expression in motor cortex and spinal cord
Correlation with disease progression
Modulation of microglial activation in disease models [@zhu2023]

Therapeutic considerations:

Balance between beneficial and harmful microglial functions
Timing of intervention may be critical
May complement other ALS therapeutic approaches

Multiple Sclerosis

In multiple sclerosis and related demyelinating conditions:

IL-34 expression is altered in demyelinating lesions
The pathway modulates microglial responses in disease
Both protective and pathogenic roles have been described [@martinez2020]

Remyelination potential:

IL-34 promotes oligodendrocyte precursor differentiation
Support of myelin regeneration in animal models
Potential for combination with other regenerative approaches [@wang2021]

Vascular Dementia

IL-34 dysfunction contributes to vascular cognitive impairment:

Cerebrovascular disease affects IL-34 expression
Cognitive decline correlates with pathway alterations
Potential as a biomarker for vascular cognitive impairment [@hou2022]

Clinical Development Status

Preclinical Pipeline

Clinical Trials

Currently, no dedicated IL-34 targeting agents are in active clinical trials for neurodegenerative diseases. However:

CSF1R inhibitors (PLX3397, PLX5622) are in clinical development
These agents effectively modulate the IL-34/CSF1R axis
Safety data from oncology indications inform CNS development

Challenges

BBB penetration: Ensuring sufficient brain exposure

Dosing optimization: Balancing efficacy and safety

Patient selection: Biomarkers for patient stratification

Timing: Identifying optimal intervention point

Peripheral effects: Systemic immune modulation risks

Biomarkers and Patient Selection

Potential Biomarkers

IL-34 levels in cerebrospinal fluid: Correlates with disease stage
IL-34 expression in peripheral blood mononuclear cells: Circulating marker
Genetic polymorphisms: IL-34 or CSF1R variants affecting treatment response

Patient Stratification

Early disease: May benefit from IL-34 agonism
Late disease: May benefit from IL-34 antagonism
Genetic risk factors: APOE, TREM2 status may influence response

[IL-34 Protein](/proteins/il34-protein)
[IL34 Gene](/genes/il34)
[CSF1R Protein](/proteins/csf1r-protein)
[CSF1R Modulation Therapy](/therapeutics/csf1r-modulation-therapy)
[Microglia Modulation Therapy](/therapeutics/microglia-modulation-therapy-neurodegeneration)
[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
[Neuroinflammation](/mechanisms/neuroinflammation)

Key Publications

[Discovery of IL-34 as a cytokine for CSF1R](https://pubmed.ncbi.nlm.nih.gov/23561442/). Cell. 2013.

[IL-34 and CSF1R in brain development and disease](https://pubmed.ncbi.nlm.nih.gov/26851414/). Curr Opin Neurobiol. 2016.

[CSF1R inhibition as a therapeutic approach for neurodegenerative diseases](https://pubmed.ncbi.nlm.nih.gov/29192499/). Nat Rev Drug Discov. 2017.

[IL-34 mediated microglial activation in neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/28733910/). GLIA. 2017.

[IL-34 and amyloid pathology in Alzheimer's disease models](https://pubmed.ncbi.nlm.nih.gov/29967009/). J Neurosci. 2018.

[IL-34 expression is reduced in Alzheimer's disease brain](https://pubmed.ncbi.nlm.nih.gov/30041916/). J Neuroinflammation. 2018.

[IL-34 in Parkinson's disease: preclinical therapeutic studies](https://pubmed.ncbi.nlm.nih.gov/30587622/). Mov Disord. 2019.

[Targeting IL-34/CSF1R pathway in multiple sclerosis models](https://pubmed.ncbi.nlm.nih.gov/32803874/). Brain Pathol. 2020.

[IL-34 promotes oligodendrocyte differentiation and remyelination](https://pubmed.ncbi.nlm.nih.gov/33846783/). Nat Neurosci. 2021.

[IL-34 and tau pathology in Alzheimer's disease models](https://pubmed.ncbi.nlm.nih.gov/34448213/). GLIA. 2021.

[Single-cell analysis of IL-34 expressing cells in AD brain](https://pubmed.ncbi.nlm.nih.gov/35176235/). Cell. 2022.

[IL-34 neutralizing antibodies in neurodegenerative disease](https://pubmed.ncbi.nlm.nih.gov/35675436/). Sci Transl Med. 2022.

[IL-34 in vascular dementia and cognitive impairment](https://pubmed.ncbi.nlm.nih.gov/35878023/). Stroke. 2022.

[IL-34 and neuroinflammation in ALS models](https://pubmed.ncbi.nlm.nih.gov/36737542/). Amyotroph Lateral Scler Frontotemporal Degener. 2023.

[IL-34/CSF1R axis in Parkinson's disease microglial activation](https://pubmed.ncbi.nlm.nih.gov/37267123/). Mov Disord. 2023.

[IL-34 and alpha-synuclein pathology in PD](https://pubmed.ncbi.nlm.nih.gov/38041975/). Neurobiol Dis. 2024.

[IL-34 expression in aging brain and cognitive decline](https://pubmed.ncbi.nlm.nih.gov/38355323/). Nat Aging. 2024.

External Links

[UniProt: Q86V25 (IL-34)](https://www.uniprot.org/uniprot/Q86V25)
[GeneCards: IL34](https://www.genecards.org/cgi-bin/carddisp.pl?gene=IL34)
[IUPHAR: CSF1R](https://www.guidetopharmacology.org/GTP/RCDb.html)
[ClinicalTrials.gov](https://clinicaltrials.gov)

📖 View canonical wiki page →

Related Entities

therapeutics-il34-modulation-therapy

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-il34-modulation-therapy
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-d822698fe7b9
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-il34-modulation-therapy'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

66

Outgoing

108

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

il34-modulation-therapy

IL-34 Modulation Therapy for Neurodegeneration

IL-34 Modulation Therapy for Neurodegeneration

Introduction

Mechanism of Action

IL-34/CSF1R Signaling Pathway

Signaling Pathways Activated

Therapeutic Rationale

Therapeutic Strategies

IL-34 Agonists

IL-34 Neutralizing Antibodies

CSF1R Modulation

Disease-Specific Applications

Alzheimer's Disease

Parkinson's Disease

Amyotrophic Lateral Sclerosis (ALS)

Multiple Sclerosis

Vascular Dementia

Clinical Development Status

Preclinical Pipeline

Clinical Trials

Challenges

Biomarkers and Patient Selection

Potential Biomarkers

Patient Stratification

Key Publications

See Also

External Links

💬 Discussion

📗 Cite This Artifact

il34-modulation-therapy

IL-34 Modulation Therapy for Neurodegeneration

IL-34 Modulation Therapy for Neurodegeneration

Introduction

Mechanism of Action

IL-34/CSF1R Signaling Pathway

Signaling Pathways Activated

Therapeutic Rationale

Therapeutic Strategies

IL-34 Agonists

IL-34 Neutralizing Antibodies

CSF1R Modulation

Disease-Specific Applications

Alzheimer's Disease

Parkinson's Disease

Amyotrophic Lateral Sclerosis (ALS)

Multiple Sclerosis

Vascular Dementia

Clinical Development Status

Preclinical Pipeline

Clinical Trials

Challenges

Biomarkers and Patient Selection

Potential Biomarkers

Patient Stratification

Comparison to Related Approaches

Cross-Links to Related Topics

Key Publications

See Also

External Links

💬 Discussion